Diagnosis & Disease Information

MPR Weekly Dose Podcast Episode 88

The FDA authorizes a postexposure prophylaxis for COVID-19; A new treatment is okay’d for lupus; A higher dose naloxone nasal spray became available; The risk evaluation and mitigation program for Clozapine has had important changes, and finally, Istodax has had an indication withdrawn.

MPR Weekly Dose Podcast 82

This week the FDA approved a regenerative skin tissue therapy and a treatment for advanced mastocytosis, while Novavax’s vaccine for COVID and a novel treatment for MDD show promise, also the FDA issue warning concering hand sanitizers.